Special to DG News NEW YORK, NY — May 19, 2002 —
The investigational selective aldosterone blocker, eplerenone, appears to be more effective in reducing blood pressure among patients with low-renin high blood pressure than is the angiotensin II receptor blocker losartan, researchers said.
“Eplerenone is effective and well tolerated, and therefore it has potential,” said lead researcher Myron Weinberger, MD, professor of medicine at the University of Indiana School of Medicine, in Indianapolis, Indiana, United States.
He presented the findings from his 16-week, randomized, double-blind study, during an oral presentation here Friday at the 17th annual meeting of the American Society of Hypertension. “Hypertensive patients with low plasma renin may be salt/volume-sensitive and should therefore respond better to aldosterone blockade than angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers,” he said.
In the study, 168 patients with an average baseline blood pressure level of 154/98 mm Hg and morning low plasma renin levels underwent a three-week washout period before being assigned to receive 100 mg of eplerenone once a day or 50 mg of losartan once a day. After one month, if the patients’ blood pressure was still not controlled to a level of less than 140/90 mmHg, the dosages were increased to 200 mg once a day of eplerenone or 100 once-a-day of losartan.
If still uncontrolled after eight weeks, physicians could add hydrochlorothiazides to the regimen, increasing the dose if blood pressure remained high at 12 weeks.
e-Med Tools
קצר קולע וממוקד
e-Med סמינרים
אי-מד תחקירים
Medscape Tools
Journal Club
מרכזי מידע ושירות
Facebook
מידע למפרסם
מאגר תרופות
מאגר אנשי המקצוע
אינדקס שימושי
חדשות משה"ב
eMed HealthClub
מחקרים קליניים
השאירו תגובה
רוצה להצטרף לדיון?תרגישו חופשי לתרום!